Cargando…
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we systematically reviewed literature in Medline/Embase for DLBCL/FL-related articles on real-world results published during January 2012–May 2016. A...
Autores principales: | Galaznik, Aaron, Huelin, Rachel, Stokes, Michael, Guo, Yelan, Hoog, Meredith, Bhagnani, Tarun, Bell, Jill, Shou, Yaping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088264/ https://www.ncbi.nlm.nih.gov/pubmed/30112190 http://dx.doi.org/10.4155/fsoa-2018-0049 |
Ejemplares similares
-
Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Ling, et al.
Publicado: (2019) -
The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021) -
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
por: Miller, Sally D, et al.
Publicado: (2022) -
Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023) -
Predicting Outcomes in Patients With Diffuse Large B-Cell Lymphoma Treated With Standard of Care
por: Galaznik, Aaron, et al.
Publicado: (2019)